Internal Server Error

Vuja De Sciences - About the company

Vuja De Sciences is a seed company based in Hoboken (United States), founded in 2017 by Raphael Nir, Richard Lampe, Robert Hurst and David Warshawsky. It operates as a Developer of therapies for preventing metastasis and recurrence of cancers. Vuja De Sciences has raised $3.94M in funding. The company has 110 active competitors, including 25 funded and 27 that have exited. Its top competitors include companies like argenx, Vor Biopharma and Radius Health.

Company Details

Developer of therapies for preventing metastasis and recurrence of cancers. It offers a lead candidate VUJ-100 that has anti metastatic activity based on properitory platform for multiple metastatic osteosarcoma and other cancer models.
Email ID
*****@vujade-life.com
Key Metrics
Founded Year
2017
Location
Hoboken, United States
Stage
Seed
Total Funding
$3.94M in 10 rounds
Ranked
Employee Count
2 as on Aug 31, 2026
Similar Companies
Sign up to download Vuja De Sciences' company profile

Vuja De Sciences's funding and investors

Vuja De Sciences has raised a total funding of $3.94M over 10 rounds. Its first funding round was on May 20, 2019.

Here is the list of recent funding rounds of Vuja De Sciences:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Oct 04, 2024
2213532
Conventional Debt
3214910
5984342
3791937
8774244
Oct 04, 2024
3141333
Seed
3264158
3528085
2545218
1704660
Feb 06, 2024
8943534
Seed
9901023
1704705
3893242
2403811
lockAccess funding benchmarks and valuations. Sign up today!

Vuja De Sciences' founders and board of directors

Founder? Claim Profile
The founders of Vuja De Sciences are Raphael Nir, Richard Lampe, Robert Hurst and David Warshawsky.
Here are the details of Vuja De Sciences' key team members:

Vuja De Sciences' employee count trend

Vuja De Sciences has 2 employees as of Aug 26. Here is Vuja De Sciences's employee count trend over the years:
Employee count trend for Vuja De Sciences
lockUncover Vuja De Sciences' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Vuja De Sciences's Competitors and alternates

Top competitors of Vuja De Sciences include argenx, Vor Biopharma and Radius Health. Here is the list of Top 10 competitors of Vuja De Sciences, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for argenx
argenx
2008, Ghent (Belgium), Public
Developer of antibody-based drugs to treat autoimmune diseases and cancer
$61.9M
75/100
2nd
Logo for Vor Biopharma
Vor Biopharma
2019, Cambridge (United States), Public
Developer of therapeutics to treat acute myeloid leukemia
$152M
68/100
3rd
Logo for Radius Health
Radius Health
2003, Boston (United States), Acquired
Biopharmaceutical company focused on bone health and related therapeutic areas
$213M
63/100
4th
Logo for Healx
Healx
2014, Cambridge (United Kingdom), Series C
Provider of AI-powered drug discovery solutions for rare diseases
$115M
62/100
5th
Logo for Horizon Therapeutics
Horizon Therapeutics
2008, Dublin (Ireland), Acquired
Developer of drugs for treating rare and autoimmune diseases
$61.8M
61/100
6th
Logo for Quince Therapeutics
Quince Therapeutics
2012, San Francisco (United States), Public
Developer of therapeutics for orthopedic diseases
$108M
60/100
7th
Logo for Angitia
Angitia
2018, Woodland Hills (United States), Series D
Developer of drugs for muscle, bone, and joint diseases
$406M
58/100
8th
Logo for Alesta Therapeutics
Alesta Therapeutics
2021, Leiden (Netherlands), Acquired
Developer of small molecule therapies for rare diseases
$67.5M
56/100
9th
Logo for Vuja De Sciences
Vuja De Sciences
2017, Hoboken (United States), Seed
Developer of therapies for preventing metastasis and recurrence of cancers
$3.94M
-
55/100
10th
Logo for Valitor
Valitor
2010, Berkeley (United States), Series B
Developer of therapeutic proteins for multiple disease conditions
$38.2M
55/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Vuja De Sciences's competitors? Click here to see the top ones

Vuja De Sciences's Investments and acquisitions

Vuja De Sciences has made no investments or acquisitions yet.

Reports related to Vuja De Sciences

Here is the latest report on Vuja De Sciences's sector:

News related to Vuja De Sciences

lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Vuja De Sciences

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford